Abstract
A 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) that protects against invasive infection by the seven most common serotypes of Streptococcus pneumoniae was licensed in February 2000. Confirmation of the vaccine's benefits now has been published. In a comparison of 2001 data with data from 1994-2000 (gathered from eight U.S. children's hospitals), researchers reported an overall yearly 58% reduction in invasive pneumococcal infections (IPI) such as meningitis, pneumonia, and bacteremia among children younger than …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
